Success for Novo's once-weekly diabetes therapy in first PhIII
This article was originally published in Scrip
Executive Summary
Novo Nordisk has reported positive results from the first of six Phase III studies of its once-weekly, modified formulation of market leading diabetes therapy Victoza (liraglutide).